China conditionally approves one-shot recombinant COVID-19 vaccine

BEIJING, China, Feb 28 – The Chinese National Medical Products Administration granted conditional market approval to a recombinant novel coronavirus vaccine that requires only one shot.

Developed by a research team led by Chen Wei, an academician at the Chinese Academy of Engineering and a researcher at the Institute of Military Medicine under the Academy of Military Sciences, it is China’s first approved COVID-19 vaccine that relies on adenovirus as the vector to deliver the coronavirus spike gene into the body.

Targeting people aged above 18, the vaccine can be transported and stored at a temperature ranging from 2 to 8 degrees Celsius.

The vaccine shows a 65.7-percent efficacy at preventing symptomatic cases and a 90.98-percent efficacy against severe disease in an interim analysis of its global phase-3 clinical trials, according to media reports. In the Pakistan subset, its efficacy at preventing symptomatic cases is 74.8 percent and 100 percent at preventing severe disease.

About The Author

XINHUA

Xinhua News Agency, founded on November 7, 1931, is China’s national news agency as well as a global news and information network. Xinhua has set up a global news and information gathering network, with headquarters in Beijing, 33 domestic bureaus in provinces, autonomous regions and municipalities plus the special administrative regions of Hong Kong and Macao, as well as 140 bureaus in the rest of the world. Xinhua is yet to set up a bureau in Taiwan, where it has posted resident correspondents. Xinhua provides its worldwide subscribers with news and financial information products in the forms of text, photo, graphics, audio, video, and mobile phone text messages 24 hours a day in eight languages: Chinese, English, French, Russian, Spanish, Arabic, Portuguese and Japanese.

See author's posts